ACE-1831 is under clinical development by Acepodia and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACE-1831’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACE-1831 is under development for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma. The therapeutic candidate comprises of off-the-shelf NK like gamma delta T cells armed with antibodies and acts by targeting CD 20 expressing hematological tumor cells. It is being developed based on the antibody-cell conjugation (ACC) technology platform. It is administered through intravenous route.
Acepodia is a biotechnology company that develops cell therapies to treat cancers. Its pipeline include ACE1702 an antibody-conjugated NK (natural killer) cell therapy targeting HER2-expressed solid tumors, ACE1831 drug against CD20-indicated hematological cancers, ACE1708 an off-the-shelf NK-like gamma delta T therapy for PD-L1 expressed solid tumors. The company is also evaluating ACE1975 and ACE2107 antibodies against solid tumors and hematological malignancies, ACE2023 for the treatment of hepatocellular carcinoma (HCC) and ACE2146 for solid tumors. Acepodia utilizes its antibody-cell conjugation (ACC) technology platform to develop immunotherapies. The company has operations in New Taipei City, Taiwan. Acepodia is headquartered in San Mateo, California, the US.
For a complete picture of ACE-1831’s drug-specific PTSR and LoA scores, buy the report here.